medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2012, Number 11

<< Back Next >>

Ginecol Obstet Mex 2012; 80 (11)

Economic analysis of parecoxib in the management of postsurgical pain in Gynecology

Muciño-Ortega E, Galindo-Suárez RM, Díaz-Ponce H, Walter- Tordecillas MA

Language: Spanish
References: 27
Page: 685-693
PDF size: 114.17 Kb.


ABSTRACT

Background: Poorly managed postoperative pain has a negative impact in healing patients and costs of care.
Methods: A model to estimate economic and health consequences of parecoxib 40 mg and morphine 12 mg regarding ketorolac 30 mg, on the management of postoperative pain in gynecologic laparotomy surgery from the perspective of the Mexican Social Security Institute (IMSS) was developed. A systematic review to identify the proportion of patients that rated their analgesic treatment as “excellent” or “good” in the Patient Global Evaluation of Study Medication, 12 hours after administration of the analgesic (responders), was performed. The patients who rated “fair” or “poor” their treatment were administered additional 4 mg of morphine. Costs in the model correspond to the acquisition costs of analgesics in which the institution would incur.
Results: The proportion and cost per responder were: morphine: 14.44% and$ 192.79, ketorolac: 32.44% and $34.82, parecoxib: 35.51% and $121.25.Treatment with morphine was more expensive and less effective than both, ketorolac and parecoxib, while the cost per additional percent point of responders with parecoxib (compared to ketorolac) was $ 28.15. For the management of postoperative pain, ketorolac and parecoxib are more effective and less expensive than morphine, additionally parecoxib would be an alternative for patients with contraindication to ketorolac use.
Conclusion: The management of postoperative pain with parecoxib is more effective and, in the context of IMSS, less expensive than morphine, also constitutes an alternative with a reasonable incremental cost compared to ketorolac.



REFERENCES

  1. Warfield CA, Kahn CH. Acute pain management: programs in US hospitals and experiences and attitudes among U.S. adults. Anesthesiology 1995;83(5):1090-1094.

  2. Apfelbaum JL, Chen C, Mehta SS, Gan TT. Postoperative pain experience: Results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003;97(2):534-540.

  3. Huang N, Cunningham F, Laurito CE, Chen C. Can we do better with postoperative pain management. Am J Surg 2001;182(5):440-448.

  4. Bader P, Echtle D, Fonteyne V, Livadas K, De Meerleer G, et al. Guidelines on pain management. European Association of Urology 2010. Disponible en: http://www.uroweb.org/ professional-resources/guidelines/.

  5. Guevara-López U, Covarrubias-Gómez A, Delille-Fuentes R, Hernández-Ortiz A, Carrillo-Esper R, et al. Parámetros de práctica para el manejo del dolor agudo perioperatorio. Cir Ciruj 2005;73(3):223-232.

  6. Tsui SL, Law S, Fok M, Lo JR, Ho E, et al. Postoperative analgesia reduces mortality and morbility after esophagetomy. Am J Surg 1997;173:472-478.

  7. Miaskowski C, Crews J, Ready LB, Paul SM, Ginsberg B. Anesthesia based pain services improve the quality of postoperative pain management. Pain 1999;80:23-29.

  8. Coley KC, Williams BA, DaPos SV, Chen C, Smith RB. Retrospective evaluation of unanticipated admissions and readmissions after some day surgery and associated costs. J Clin Anesth 2002;14:349-53.

  9. Burke JP, Pestotnik SL, Classen DC, Lloyd JF. Evaluation of the financial impact of ketorolac tromethamine therapy in hospitalized patients. Clin Ther 1996;18:197-211.

  10. Gora-Harper ML, Record KE, Darkow T, Tibbs PA. Opioid anagesics versis ketorolac in spine and joint procedures: impact on healthcare resources. Ann Pharmacother 2001;35:1320-1326.

  11. Wa t c h a MF, I s s i o u i T, K l e i n KW, Wh i t e P F. C o s t a n d e f f e c t i v e n e s s o f r o f e c o x i b , c e l e c o x i b , a n d a c e t ami n o p h e n f o r p r e v e n t - ing af ter ambulator y otolar yngologi c surger y. Anesth Analg 2003;96:987-994.

  12. Tilleul P, Weickmans H, Sean PT. Cost analysis applied to postoperative analgesia regimens: a comparison between parecoxib and propacetamol. Pharm World Sci 2007:29:374-379.

  13. Consejo de Salubridad General. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. Cuadro básico de medicamentos, Grupo 10: Hematología. Disponible en: http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/ medicamentos/medicamentos_ ed2010.pdf.

  14. Bikhazi B, Snabes M, Bajwa Z, Davis D, LeComte D, et al. A clinical trail demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. Am J Obstet Gynecol 2004;191:1183-1191.

  15. Ma l a n T P, Go r d o n S , Hu b b a r d R, S n a b e s M. T h e c y c l o o x y g e n a s e - 2 - s p e c i f i c i n h i b i t o r parecoxib sodium is as effect ive as 12 mg of mo r p h i n e a dmi n i s t e r e d i n t r amu s c u l a r l y f o r treating pain after gynecologic laparotomy surgery. Anesth Analg 2005;100(2):454-60.

  16. J e n s e n MP, Me n d o z a T, Ha n n a DB , Ch e n C, Cl e e l a n d CS. Th e a n a l g e s i c e f f e c t s t h a t underlie patient satisfaction with treatment. Pain 2004;110:480- 487.

  17. Da n i e l s S E , Gr o s sma n EH, K u s s ME , Ta l - w a l k e r S , H u b b a r d R C . A d o u b l e b l i n d r a n d omi z e d c omp a r i s o n o f i n t r amu s c u l a r - l y a n d i n t r a v e n o u s l y a dmi n i s t e r e d p a r e c o x i b s o d i u m v e r s u s k e t o r o l a c a n d p l a c e - bo in post -oral surgery pain model . Cl in Ther 2001;23:1018-31.

  18. Launtsen J, Moller AM. Publications in anesthesia journals: Quality and clinical relevance. Anesth Analg 2004;99:1486- 1491.

  19. J a d a d AR, Mo o r e RA, Ca r r o l l D, J e n k i n s o n C, Reynolds DJM, et al . Assessing the qual i t y of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 17:1-12.

  20. Lloyd R, Deny S, Moore RA, McQuay HJ. Intravenous or intramuscular parecoxib for acute postoperative pain in adults (Review). The Cochrane Library 2010, Issue 1.

  21. Secretaría de la Función Pública México). Fallo de adquisición a licitaciones públicas Nos. LA-019GYR047-T59-2011 (morfi na) y OA-019GRY047-N53-2011 (ketorolaco). Disponible en www.compranet.com.mx.

  22. Kranke P, Morin A, Roewer N. Patients global evaluation of analgesia and safety of injected Parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg 2004;99:797- 798.

  23. T i l l e u l P, We i c kma n s H , S e a n P T, L i e n - har t A, Beaussier M. Cost analysis appl ied to pos toperat i ve analges ia regimens : a compar i - s o n b e twe e n p a r e c o x i b a n d p r o p a r a c e t amo l . Pharm World Sci 2007;29:374-379.

  24. Ra i n e r TH, J a c o b s P, Ng YC, Ch e u n g NK, Tarn M, et al . Cos t ef fec t i venes s anal y s i s of int ravenous ketorolac and morphine for t reat - i n g p a i n a f t e r l imb i n j u r y : d o u b l e b l i n d randomized controlled trial. BMJ 2000;321;1247.

  25. M a l a n T P, M a r s h G , H a k k i S I , G r o s s - man E, Traylor L, et al . Parecoxib sodium, a parenteral cyclooxigenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip artroplasty. Anesthesiology 2003;98:950-956.

  26. Hubbard RC, Naumann TM, Tray lor L, Dhadd a S. Pa r e c o x i b s o d i um h a s o p i o i d - s p a r i n g effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth 2003;90:166-172.

  27. Ph i l i p BK, Re e s e PR, Bu r c h SP. T h e Ec o - nomic Impact of Opioids on Postoperative Pain Management. J Clin Anesth 2002; 14(5): 354-64.




2020     |     www.medigraphic.com